View Older Stories View More Recent Stories
-
ROSEN, A LEADING LAW FIRM, Encourages BioAge Labs, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIOA
-
BIOAGE LABS (BIOA) Investors are Notified the Company has been Sued and are Urged to Contact BFA Law by March 10
-
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioAge Labs, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIOA
-
BIOA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, A LEADING LAW FIRM, Encourages BioAge Labs, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIOA
-
BIOA INVESTOR DEADLINE: BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
BIOA COURT UPDATE: BFA Law Reminds BioAge Labs Investors to Contact the Firm by the Upcoming March 10 Class Action Deadline
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIOA
-
BioAge Labs (BIOA) Faces Securities Class Action On Behalf Of IPO Investors After Discontinuing Weight-Loss Drug Trial- Hagens Berman
-
BIOA SHAREHOLDER REPORT: BioAge Labs Investors with Losses are Notified to Contact BFA Law before Expiration of March 10 Class Action Deadline
-
ROSEN, A LEADING LAW FIRM, Encourages BioAge Labs, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIOA
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs
-
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIOA
-
BIOA CLASS ACTION DEADLINE: BioAge Labs, Inc. Investors are Notified of Pending Class Action and are Urged Contact BFA Law before March 10 Deadline
-
ROSEN, A HIGHLY-REGARDED LAW FIRM, Encourages BioAge Labs, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIOA
-
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BIOA
-
BIOA LEGAL NEWS: BFA Law Announces that a Class Action Lawsuit has Been Filed Against BioAge Labs, Inc. and Urges Investors with Losses to Contact the Firm
-
BIOA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
BIOA ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of BioAge Labs, Inc. Investors
-
BIOA CLASS ACTION ALERT: BFA Law Alerts BioAge Labs, Inc. Investors that a Class Action has been Filed and Urges You to Contact BFA Law
-
BIOA INVESTIGATION UPDATE: BFA Law Notifies BioAge Labs Investors with Losses of Continuing Legal Investigation and Urges You to Contact the Firm
-
BIOA STOCK NOTICE: BioAge Labs Investors are Notified to Contact BFA Law About Its Investigation into the Company's 76% Stock Drop
-
BIOA STOCK NOTIFICATION: BioAge Labs Investors are Alerted the Company is Under Investigation and are Urged to Contact BFA Law
-
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman
-
BIOA STOCK ALERT: BFA Law Alerts BioAge Labs Investors that the Company is being Investigated after Stock Plummeted 76% and Urges You to Contact the Firm
-
BIOA INVESTOR NOTICE: BioAge Labs, Inc. Investors that Lost Money are Notified to Contact BFA Law about its Continuing Investigation into the Company
-
BIOA INVESTMENT REMINDER: BioAge Labs Investors that Suffered Losses are Notified to Contact BFA Law about its Ongoing Investigation
-
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against BioAge Labs, Inc. (BIOA)
-
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman
-
BIOA INVESTMENT ALERT: BioAge Labs Investors are Reminded to Contact BFA Law about its Investigation into the Discontinuation of the Phase 2 Trial
-
BIOA NEWS: BioAge Labs Investors are Notified of an Investigation into the Discontinuation of the Phase 2 Study and are Urged to Contact BFA Law
-
BIOA INVESTIGATION NOTICE: BFA Law Alerts BioAge Labs Investors a Securities Investigation has been Initiated and Encourages You to Contact the Firm
-
BIOA SHAREHOLDER REPORT: BioAge Labs Investors are Notified the Company is Being Investigated and are Urged to Contact BFA Law
-
BioAge Labs (BIOA) Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
-
BIOA INVESTOR NEWS: BioAge Labs, Inc. Investors with Losses Are Notified of Continuing Investigation and Are Urged to Contact BFA Law
-
BIOA INVESTOR NEWS: BioAge Labs, Inc. Investors with Losses are Notified of Continuing Investigation and are Urged to Contact BFA Law
-
BIOA INVESTOR ALERT: BioAge Labs Investors are Alerted of Ongoing Investigation into the 76% Stock Drop and are Encouraged to Contact BFA Law
-
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman
-
BIOA INVESTOR ALERT: BioAge Labs Investors Should Contact Block & Leviton To Learn More About Fraud Investigation
-
Morgan Stanley Downgrades BioAge Labs Inc (BIOA) to Underweight
-
BioAge Labs (BIOA) Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
-
Citi Downgrades BioAge Labs Inc (BIOA) to Neutral
-
Jefferies Downgrades BioAge Labs Inc (BIOA) to Hold
-
Citi Starts BioAge Labs Inc (BIOA) at Buy
-
Jefferies Starts BioAge Labs Inc (BIOA) at Buy
-
Morgan Stanley Starts BioAge Labs Inc (BIOA) at Overweight
-
BioAge Labs (BIOA) opens at $22.50, IPO priced at $18
-
Bioage Labs (BIOA) Opens At $22.50, IPO Priced At $18
-
BioAge Labs (BIOA) Announces Upsized 11M Share Offering at $18/sh
